The challenge of cardiovascular toxicity evaluation

The evaluation of cardiovascular toxicity is a significant challenge in drug development. Preclinical evaluation of cardiovascular safety involves a multifaceted approach, encompassing a plethora of in vitro and in vivo endpoints.

These assessments continuously evolve, aiming to mitigate the incidence of cardiovascular toxicity that may emerge during clinical trials.

To shed light on the intricate dynamics of cardiovascular toxicity, let’s examine the case of two distinct small-molecule inhibitors, Compound A and Compound B, described in a recent study¹ by Yevgeniya E. Koshman et al.